title: Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
authors.forename: John M
authors.initials: JM
authors.lastname: Nicholls
authors.forename: Laura M
authors.initials: LM
authors.lastname: Aschenbrenner
authors.forename: James C
authors.initials: JC
authors.lastname: Paulson
authors.forename: Erin R
authors.initials: ER
authors.lastname: Campbell
authors.forename: Michael P
authors.initials: MP
authors.lastname: Malakhov
authors.forename: David F
authors.initials: DF
authors.lastname: Wurtman
authors.forename: Mang
authors.initials: M
authors.lastname: Yu
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001422:Bacterial Adhesion; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D007251:Influenza, Human / Q000517:prevention & control*; D037102:Lectins / Q000378:metabolism; D009439:Neuraminidase / Q000494:pharmacology / Q000627:therapeutic use*; D011008:Pneumococcal Infections; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D020545:Respiratory Mucosa / Q000737:chemistry; D013296:Streptococcus pneumoniae / Q000502:physiology
chemical_list: D000998:Antiviral Agents; D037102:Lectins; D011994:Recombinant Proteins; D009439:Neuraminidase